mCRC Daily News from ASCO 2014: May 30, 2014 – Preview of Key Topics
The presentations at ASCO 2014 will be providing a comprehensive review of important research developments in metastatic colorectal cancer (mCRC). Moreover, many of the presentations will help attendees with their clinical decision-making in treating patients with mCRC. Here is our Top 10 List that includes many of the key topics in mCRC to be discussed during ASCO 2014:
- Optimal therapies for KRAS-mutant and KRAS?wild-type mCRC
- The value of adjuvant chemotherapy
- Maintenance therapy in mCRC—important updates to CAIRO-3 and SAKK
- Optimal use of molecular biomarkers to distinguish among CRC subtypes and to inform therapy
- Head-to-head comparison of bevacizumab and cetuximab in KRAS?wild-type CRC—the long-awaited results of the CALGB/SWOG 80405 trial
- Optimal adjuvant chemotherapy for curatively resected rectal cancer
- Gene sequence discordance between primary and metastatic mCRC tissue—implications for therapy
- New developments in the use of early predictors of positive long-term outcomes of first-line therapy
- Emerging molecular targets in mCRC—should we be testing for BRAF V600 mutations?
- New predictive biomarkers of cetuximab efficacy
The ASCO Conference E-Highlight Reports over the next several days will provide details of these and other important, potentially practice-changing advances in the management of patients with mCRC. Moreover, the key theme for ASCO 2014 is “Science and Society,” in which the value proposition of cancer care in mCRC will be integrated into many presentations and discussed separately at unique stand-alone sessions on value-based issues in oncology. We will include this critical 3-dimensional view of advances in mCRC therapy in our reports.